title: [Medical treatment of bladder carcinoma].
abstract: OBJECTIVE
  To describe drugs used in bladder carcinoma.
  
  
  METHODS
  Pubmed search for efficacy, mode of action and side effects for each molecule. Additional data were searched from the French regulatory agencies web sites (HAS and ANSM).
  
  
  RESULTS
  The drugs used in the treatment of bladder cancer are represented by the products referred to diagnosis (hexyl aminolevulinate), the intravesical instillations for the treatment of tumors not infiltrating the muscle and the infiltrating tumor chemotherapy (neo-adjuvant treatment or metastatic tumors). The hexyl aminolevulinate cystoscopy allows to identify a significantly greater number of lesions, including carcinoma in situ, compared to conventional white light cystoscopy. For intravesical instillations, BCG has a superior efficacy to mitomycin C with a lower tolerance. The chemotherapies for invasive tumors are effective in metastatic disease in 15-20% of cases with a mean survival of 12 to 14 months.
  
  
  CONCLUSIONS
  Except the use of hexyl aminolevulinate for improving the diagnosis, there was no emergence in recent years of new drugs for the treatment of bladder cancer. Targeted therapies currently available for many neoplasms were ineffective for bladder cancer.
authors.affiliation: Faculté de médecine, université d'Auvergne, 28, place Henri-Dunant, BP 38, 63001 Clermont-Ferrand cedex 1, France; Service d'urologie, hôpital G.-Montpied, 58, rue Montalembert, 63003 Clermont-Ferrand cedex 1, France. Electronic address: lguy@chu-clermontferrand.fr.
authors.forename: L
authors.initials: L
authors.lastname: Guy
authors.forename: H
authors.initials: H
authors.lastname: Mahammedi
authors.forename: C
authors.initials: C
authors.lastname: Bastide
authors.forename: F
authors.initials: F
authors.lastname: Bruyere
authors.forename: G
authors.initials: G
authors.lastname: Karsenty
authors.forename: J-O
authors.initials: JO
authors.lastname: Bay
mesh_terms: D000622:Aminolevulinic Acid / Q000031:analogs & derivatives; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001500:BCG Vaccine / Q000627:therapeutic use; D002277:Carcinoma / Q000175:diagnosis / Q000188:drug therapy*; D002945:Cisplatin / Q000627:therapeutic use; D003558:Cystoscopy; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005453:Fluorescence; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D016685:Mitomycin / Q000627:therapeutic use; D017319:Photosensitizing Agents; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D014747:Vinblastine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000093542:Gemcitabine
chemical_list: D000903:Antibiotics, Antineoplastic; D001500:BCG Vaccine; D017319:Photosensitizing Agents; D003841:Deoxycytidine; D016685:Mitomycin; C111217:vinflunine; D014747:Vinblastine; D004317:Doxorubicin; D000622:Aminolevulinic Acid; C419924:5-aminolevulinic acid hexyl ester; D002945:Cisplatin; D008727:Methotrexate; D000093542:Gemcitabine
keywords: BCG; Bladder cancer; Bladder instillations; Cancer de la vessie; Chemotherapy; Chimiothérapie; Diagnosis; Diagnostic; Instillations endovésicales